BioSpace News Archive

Drug Development

Urovant Sciences Initiates Phase 3 Clinical Program for Vibegron in Patients with Overactive Bladder

Pivotal trial will enroll approximately 1,400 patients for 12-week treatment period.

March 28, 2018
·
3 min read
Business

Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2017 Financial Results

Alpine Immune Sciences, Inc. provided a corporate update and reported financial results for the year ended December 31, 2017.

March 28, 2018
·
6 min read
Drug Development

MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix® Injectable For The Treatment Of Osteoarthritis Of The Knee

Initiation of Phase 2B Study Follows Quickly After FDA Grants RMAT Designation for Knee OA.

March 28, 2018
·
4 min read
Business

Sarah Wilkinson, CEO of NHS Digital, Named U.K. Chief Digital Officer of the Year 2017 by CDO Club

Ms. Wilkinson was presented with the award after her keynote on “Digitising the National Health Service” at the 3rd U.K. CDO Summit in London, England, by CDO Club founder David Mathison.

March 28, 2018
·
4 min read
Business

bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States

bluebird and Celgene will share 50% of U.S. costs and profits

March 28, 2018
·
5 min read
Deals

PTC Therapeutics Announces Pricing of Public Offering of Common Stock

PTC Therapeutics, Inc. announced the pricing of a public offering of 4,000,000 shares of its common stock at a public offering price of $27.04 per share, before underwriting discounts.

March 28, 2018
·
2 min read
Business

Alliar Announces 4Q17 Results

Centro de Imagem Diagnósticos SA announces its results for the fourth quarter of 2017 (4Q17).

March 28, 2018
·
1 min read
Business

Regional Health Properties Postpones Conference Call to Discuss Fourth Quarter and Year End 2017 Financial Results

Regional Health Properties, Inc. announced postponing the release of its financial results for the fourth quarter and full-year period ended December 31, 2017 and its previously announced conference call to discuss such results originally scheduled for March 29, 2018.

March 28, 2018
·
1 min read
Drug Development

Prometic Reports Positive Clinical Data From Ongoing PBI-4050 Study in Alström Syndrome Patients

Clinical benefits in both heart and liver observed in patients treated with PBI-4050 over an average of 52 weeks of treatment.

March 28, 2018
·
7 min read
Toshiba Heavy-Ion Therapy System Awarded by Yonsei University Health System

Toshiba Energy Systems & Solutions Corporation in collaboration as a consortium with DK Medical Solutions is awarded a contract to supply a heavy-ion therapy system to Yonsei University Health System (YUHS), one of the leading providers of medical services in Korea.

March 28, 2018
·
3 min read